Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer

BACKGROUND: Trastuzumab and pertuzumab target the Human Epidermal growth factor Receptor 2 (HER2). Combination therapy has been shown to provide enhanced antitumour activity; however, the downstream signalling to explain how these drugs mediate their response is not clearly understood. METHODS: Tran...

Descripción completa

Detalles Bibliográficos
Autores principales: Sims, A H, Zweemer, A JM, Nagumo, Y, Faratian, D, Muir, M, Dodds, M, Um, I, Kay, C, Hasmann, M, Harrison, D J, Langdon, S P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3364568/
https://www.ncbi.nlm.nih.gov/pubmed/22549178
http://dx.doi.org/10.1038/bjc.2012.176

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3364568/
https://www.ncbi.nlm.nih.gov/pubmed/22549178
http://dx.doi.org/10.1038/bjc.2012.176

Ejemplares similares